The Race to Own the Future of Metabolic Medicine
The next generation of weight loss medicines is no longer a future story. It is happening now, and the companies racing to lead this market are moving quickly. In August 2026, Eli Lilly opened limited early access to retatrutide, an investigational triple-hormone medicine, while Pfizer signaled its own move into the field with berobenatide. The anti-obesity market is projected to reach $190 billion by 2035.1
For patients, the question is not whether the science is moving fast. It is. The harder questions are who can actually access these medicines, when that access may expand, and what it could cost. This article explains the growing competition around metabolic peptides, what makes retatrutide different, and what the current early-access program really means.
Key Takeaways
- In the Phase 3 TRIUMPH-1 trial, retatrutide was associated with an average 28.3% body-weight reduction at 80 weeks.
- Lilly’s expanded access program is not a public launch. It’s a narrow pathway for adults with refractory obesity and serious related health complications who cannot join a clinical trial.
- Insurance generally does not cover investigational medicines provided through expanded access programs.
- Pfizer’s investigational competitor, berobenatide, adds momentum to a crowded race for the next generation of metabolic medicines.
Eli Lilly Expands Early Access to Retatrutide
Lilly’s current early access program traces back to one compassionate-use case. In April 2026, the company granted a 79-year-old patient special access to retatrutide after an application from a senior National Institutes of Health clinician described refractory obesity, obstructive sleep apnea, and pulmonary hypertension. The case was not initially presented as a broad public program.
After STAT News reported the case in June, other clinicians said they had sought similar access for their own patients and had received little or no information from Lilly. On August 3, the company confirmed that it would review physician requests for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial.2
Who Qualifies for Early Access?
The reported eligibility bar is intentionally high. A patient must be 18 or older, unable to join a clinical trial, have refractory obesity, meaning obesity that has not responded adequately to available treatment, and be under active medical care for at least two serious or life-threatening obesity-related complications. Reports differ slightly on whether a patient must have tolerated the highest approved dose of an existing obesity medicine or must have discussed all standard options with a clinician.2,3
That leaves out most people who may be interested in retatrutide. Obesity specialists interviewed by The American Journal of Managed Care expected very high demand and raised questions about how requests will be reviewed, how long decisions may take, and whether treatment would be tied to trial sites.3
Insurance and the FDA Timeline
FDA guidance states that private insurers, Medicare, and other third-party payers do not cover investigational medical products obtained through expanded access.4 Lilly has not publicly disclosed the cost of retatrutide through this program. Even if a patient qualifies, the financial responsibility for the medicine and related care may remain a barrier.
Lilly has said it plans to submit a biologics license application for retatrutide in the first quarter of 2027.3 That is the formal request a company makes to the FDA for permission to market a biologic medicine. A submission is not an approval, and does not guarantee when, or whether, the product will become broadly available.
Why Retatrutide Is Different
Retatrutide is designed to activate three receptors involved in metabolic signaling: GLP-1, GIP, and glucagon. Semaglutide activates GLP-1. Tirzepatide activates GLP-1 and GIP. Retatrutide’s additional glucagon activity is one reason researchers are watching the drug closely, although its full clinical role will continue to be evaluated through the Phase 3 program.5
In the TRIUMPH-1 study of 2,339 adults with obesity, participants assigned to the highest studied retatrutide dose had an average 28.3% body-weight reduction at 80 weeks. In an extension reported for participants with severe obesity, the highest-dose group had an average 30.3% reduction at 104 weeks. These are trial results, not a guarantee of an individual outcome, and they are not a head-to-head comparison with bariatric surgery.5
How the leading investigational and approved medicines differ
| Medicine | Receptors targeted | Reported trial result | Current status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | About 13.7% average weight loss at 72 weeks | FDA approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP | About 20.2% average weight loss at 72 weeks | FDA approved |
| Retatrutide | GLP-1 + GIP + glucagon | 28.3% average body-weight reduction at 80 weeks in TRIUMPH-1 | Investigational; limited expanded access |
| Berobenatide | Not yet fully disclosed | Early Phase 2b results reported by Pfizer’s acquired developer. Phase 3 VESPER-6 trial underway now. | Investigational |
Pfizer’s Next Move: Berobenatide
Retatrutide may be leading the headlines, but it won’t have the field to itself for long. In November 2025, Pfizer acquired Metsera, the company developing berobenatide. The move positioned Pfizer to compete directly in the rapidly expanding metabolic medicine market.1
Unlike retatrutide, which targets GLP-1, GIP, and glucagon, berobenatide is an ultra-long-acting GLP-1 receptor agonist. This may mean berobenatide could be taken once a month instead of weekly like all others. Early Phase 2b reporting described a nearly 16% weight loss at 32 weeks without an observed plateau at that point. The Phase 3 VESPER-6 trial is underway now.
Pfizer has indicated plans for 20+ new clinical trials for drugs targeting weight management and other obesity-related conditions.1
What the Race for Dominance Means for Patients
Competition can create more research, more options, and eventually more pressure to address access. But it can also create confusion. New drug announcements, early access programs, clinical trial headlines, and online marketing often arrive faster than practical information about eligibility, coverage, or FDA status.
More competition could eventually put pressure on pricing, but new medicines alone won’t solve the access problem if insurance coverage and out-of-pocket costs remain out of reach. Until approved care becomes more attainable, some patients may still be drawn to grey-market products, even as regulators warn that products marketed as retatrutide outside official clinical trials or Lilly’s limited access pathway are not authorized.6,7
The next step for anyone with questions is not to chase a headline, but to talk with a qualified healthcare provider who can help explain what is approved, what is being studied, and which questions are worth asking in the context of a person’s own health history.
Important Considerations
Retatrutide remains an investigational medicine. Lilly expects to submit its FDA application in 2027, but the FDA has not approved it for general marketing or broad patient access.
The formal pathway is limited to narrowly defined patients with serious medical need who cannot participate in a clinical trial.
FDA patient guidance says investigational products received through expanded access are usually not covered by third-party payers, including private insurance and Medicare.
The authentic investigational product discussed in Lilly’s trials and formal program is not the same as products marketed online under the retatrutide name.
Clinical trial averages describe groups of participants. They do not predict a particular person’s outcome or determine what is appropriate for that person.
The Bottom Line
Retatrutide’s trial data have made it one of the most closely watched investigational metabolic medicines. Lilly’s limited expanded access program offers a pathway for a small group of patients with serious medical need, not broad availability. Pfizer’s move with berobenatide confirms that the next phase of metabolic peptide research will be fiercely competitive.
For patients, the headlines matter. But FDA status, access requirements, insurance coverage, and qualified medical guidance matter just as much. The goal is not to chase the next big name. It is to understand what is real, what is still being studied, and what questions to bring to a provider.
Semaglutide targets one receptor, GLP-1. Tirzepatide targets two, GLP-1 and GIP. Retatrutide is designed to target GLP-1, GIP, and glucagon. Researchers are studying whether this third target helps explain the larger average body-weight reductions reported in retatrutide trials.
No. Lilly has described a narrow pathway for adults who cannot join a clinical trial, have refractory obesity, and are under active care for at least two serious obesity-related complications. A qualified healthcare provider must evaluate whether a patient may meet those criteria.
Usually not. FDA patient guidance says investigational medical products received through expanded access are usually not covered by private insurance, Medicare, or other third-party payers. Coverage after any future FDA approval would depend on an individual’s health plan and benefit rules.
Berobenatide is an investigational metabolic medicine acquired by Pfizer through its purchase of Metsera. Early clinical reporting has drawn attention, but the medicine remains in development and is not FDA approved.
Scientific References
- Pfizer’s next weight loss weapon: how berobenatide stacks up. The Motley Fool. Published August 7, 2026. Accessed August 12, 2026.
- Lawrence L, Chen E. Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. STAT News. Published August 3, 2026. Accessed August 12, 2026.
- Grossi G. Lilly expands retatrutide access amid doctor pushback. The American Journal of Managed Care. Published August 5, 2026. Accessed August 12, 2026.
- US Food and Drug Administration. Expanded access: information for patients. Published November 7, 2022. Accessed August 12, 2026.
- Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1 trial. The American Journal of Managed Care. Published May 21, 2026. Accessed August 12, 2026.
- Obesity Action Coalition. Statement about grey-market GLP-1 products and safe obesity care. Published December 12, 2025.
- US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated June 15, 2026. Accessed August 12, 2026.
Legal & Medical Disclaimer
The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.
©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.
Related Posts
Ready to take the next step?
Find a verified peptide therapy provider or list your practice and connect with patients actively seeking trusted care.